Stemline Therapeutics is working on ways to eradicate cancer stem cells (CSC) and tumors. The development-stage biopharmaceutical company's pipeline includes three lead clinical-stage candidates (SL-401, SL-701, and SL-801) for leukemia and brain cancer in children and adults. Its drugs work by targeting CSCs, which are believed to be the seeds of tumors that often survive traditional cancer treatment. Stemline is part of the biopharma race to be the first to successfully kill CSCs and usher in a new era of cancer drugs. Once its candidates are approved, the company intends to create an in-house sales and marketing team for North America and Europe.